triazoles has been researched along with Response Evaluation Criteria in Solid Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
1 trial(s) available for triazoles and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; China; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Taiwan; Triazoles | 2018 |
1 other study(ies) available for triazoles and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |